Immuno-SAFE: a first-in-class saliva-based genetic test for early prediction of immune-related adverse events in non–small cell lung cancer immunotherapy

Obiettivo generale

To advance precision oncology by implementing Immuno-SAFE, a rapid and non-invasive system predicting severe irAEs in NSCLC patients eligible for anti-PD-1/PD-L1 immunotherapy. The project aims to improve treatment personalization, enhance patient safety, reduce avoidable hospitalizations, and support the regional and national transition toward more efficient, sustainable immunotherapy management.

Risultati attesi

Early and accurate identification of NSCLC patients at high risk of severe irAEs, enabling more personalized and safer immunotherapy pathways. Reduction of treatment interruptions, emergency admissions, and irAE-related healthcare costs. Strengthened precision oncology services across regional cente…